易瑞生物实控人方40天减持1105万股 套现1.25亿元

Core Viewpoint - Erye Biological (300942.SZ) announced a significant reduction in shareholding by its controlling shareholder Erye (Hainan) Venture Capital Co., Ltd. and actual controller Zhu Hai, indicating a strategic shift in ownership structure [1][2]. Summary by Relevant Sections Shareholding Changes - From September 2 to September 5, 2025, Erye Venture Capital and Zhu Hai collectively reduced their holdings in Erye Biological by 4,167,032 shares, representing 1.0287% of the total share capital [1]. - Post-reduction, the total shares held by Erye Venture Capital and Zhu Hai decreased from 238,293,404 shares to 234,126,372 shares, reducing their ownership percentage from 58.8279% to 57.7992% [1]. Total Reduction Overview - As of September 5, 2025, the total shares reduced by Erye Venture Capital and Zhu Hai amounted to 11,052,532 shares, accounting for 2.7286% of the total share capital [1]. - The reduction plan has been fully implemented [1]. Transaction Details - Erye Venture Capital sold 3,531,208 shares through block trading at an average price of 10.66 CNY per share between September 1 and September 5, 2025 [2]. - Zhu Hai sold 3,626,200 shares via centralized bidding at an average price of 12.96 CNY per share from August 6 to September 5, 2025 [2]. - Additionally, Zhu Hai sold 3,895,124 shares through block trading at an average price of 10.37 CNY per share from July 28 to September 4, 2025 [2]. - The total amount from these share reductions was approximately 125 million CNY [2].